Drugs / gp96-Ig Vaccine
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT01799161 Comparator | Dec 2014 → Apr 2018 | non-small cell lung carcinoma | Eckhard Podack | Withdrawn | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | gp96-Ig Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01799161 ↗ |
| Action | Activate | “Tumor secreted gp96 activates dendritic cells (DC), natural killer cells (NK) and cytotoxic T lymphocytes (CTL).” NCT01799161 ↗ |
| Modality | Vaccine | “heat shock protein gp96 Ig-secreting, allogeneic tumor cell-vaccine (gp96-Ig vaccine)” NCT01799161 ↗ |